Broad Institute

JUNE 10, 2024

In 2021, Liu’s lab reported a key step towards this goal and developed a prime editing approach called twinPE that installed recombinase “landing sites” in the genome, and then used natural recombinase enzymes such as Bxb1 to catalyze the insertion of new DNA into the prime edited target sites.

DNA 144

DNA Engineering Therapies Disease 144

The Pharma Data

DECEMBER 20, 2020

20 , 2020 /PRNewswire/ — The broad spectrum antiviral therapeutic, ‘hzVSF-v13(humanized Virus Suppressing Factor)’ being developed by ImmuneMed , is on track to progress as a treatment for the COVID-19 pneumonia patients. CHUNCHEON, South Korea , Dec.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

The Pharma Data

JANUARY 21, 2021

Researchers randomized patients to either 4,200 mg of IV-administered bamlanivimab or placebo and saw that after eight weeks of participant follow-up, the 965 participants who tested negative for the virus at baseline saw a 57 percent lower frequency of symptomatic COVID-19 in the drug arm compared to the placebo arm. James Miessler.

Nurses 52

Nurses Research Laboratories Laboratories Virus 52

The Pharma Data

FEBRUARY 1, 2021

1, 2021 – The National Institutes of Health has launched a new database to collect information and biospecimens from people who have experienced neurological problems associated with severe acute respiratory syndrome coronavirus 2 infection. © 2021 HealthDay. . © 2021 HealthDay. . © 2021 HealthDay. Professional.

Virus 52

Virus Treatment Research 52

The Pharma Data

JANUARY 27, 2021

– Second Product Candidate Expected to Enter Clinic in First Half of 2021. Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Disease-Modifying Therapy Options. PHILADELPHIA, Jan. About Passage Bio.

Therapies 52

Therapies Clinical Trials Treatment FDA 52

The Pharma Data

JANUARY 3, 2021

04, 2021 (GLOBE NEWSWIRE) — Passage Bio , Inc. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the company’s lead product candidate, PBGM01, an adeno-associated virus (AAV)-delivery gene therapy that is being studied for the treatment of infantile GM1 gangliosidosis (GM1).

Therapies 52

Therapies FDA Treatment Clinical Trials 52

The Pharma Data

SEPTEMBER 5, 2021

Under the agreement, AstraZeneca commits to deliver 60 million doses of the vaccine by the end of the third quarter 2021, 75 million by the end of the fourth quarter 2021 and 65 million by the end of the first quarter 2022. Legal proceedings by the European Commission against AstraZeneca were initiated in Brussels on 21 April 2021.

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

The Pharma Data

DECEMBER 2, 2020

MTX-COVAB was also found to have virus neutralizing potency (IC50= 40pM), which is comparable or better to that of the leading antibody therapies in development, and cross-neutralizes all clinically relevant virus mutants. Our GMP material will be ready in December 2020, enabling us to start clinical studies in March 2021,” said Dr.

Disease 52

Disease Virus Treatment Therapies 52

The Pharma Data

JANUARY 21, 2021

21, 2021 /PRNewswire/ — Senhwa Biosciences, Inc. Senhwa’s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. FDA for the treatment of Cholangiocarcinoma. TAIPEI and SAN DIEGO , Jan.

Trials 40

Trials Treatment Small Molecule Hospitals 40

The Pharma Data

OCTOBER 28, 2020

Food and Drug Administration as part of its review of our Emergency Use Authorization submission, and we continue to focus on completing our ongoing trials evaluating REGN-COV2 for the treatment and prevention of COVID-19.” Serious adverse events were numerically more frequent with placebo than REGN-COV2 treatment (0.8%

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

SEPTEMBER 17, 2020

The illness of one of the participants in the Oxford-AstraZeneca COVID-19 vaccine trial may not have been caused by the treatment itself, according to newly revealed information. . It uses a weakened version of the common cold virus and the genetic material of COVID-19’s spike protein. . Photo by Retha Ferguson. Conor Kavanagh.

Vaccine 52

Vaccine Trials Virus Treatment 52

The Pharma Data

JANUARY 12, 2021

13, 2021 09:39 UTC. INCHEON, South Korea–( BUSINESS WIRE )– Celltrion Group today announced top-line results from its randomised, double-blind, and placebo controlled global Phase II/III clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. days quicker compared to placebo. days; 95% C.I,

Clinical Trials 40

Clinical Trials Treatment Trials Virus 40

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

OCTOBER 27, 2021

The research opens up the possibility for the development of passive immunization or treatment against SARS-CoV-2 infection. The technique combines the advantages of using an antigen that closely resembles its state on the surface of the native virus with the biosafety advantages related to using a recombinant immunogen. 2 variants.

Clinical Trials 52

Clinical Trials Virus Production Treatment 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Posted: January 2021. Source: AstraZeneca . Source link.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Posted: January 2021. Source: AstraZeneca. Source link.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 24, 2021

Their world-class physicians set new standards in comprehensive urologic patient care and continue to innovate with the most advanced treatments backed by clinical research. MU has 70+ physicians and 47 locations located throughout the region. The MU team thrives on pushing the envelope of what’s possible in urological medicine.

Pharmaceutical Companies 52

Pharmaceutical Companies Virus Clinical Research Pharmaceuticals 52

The Pharma Data

JANUARY 8, 2021

8, 2021 — As Americans await their COVID-19 shot, a new study of a different vaccine shows the power of Facebook posts in fueling “anti-vax” resistance to immunization. © 2021 HealthDay. Posted: January 2021. FRIDAY, Jan. The data suggest the posts had momentum over time. The report was published Jan.

Vaccine 52

Vaccine Doctors Virus Disease 52

The Pharma Data

JANUARY 4, 2021

05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. MUNICH, Germany, Jan.

Therapies 52

Therapies Virus Disease Licensing 52

The Pharma Data

JULY 12, 2021

In addition, Merck plans to initiate a clinical program to evaluate molnupiravir for post-exposure prophylaxis in the second half of 2021. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

NOVEMBER 23, 2020

23, 2020 — Fresh takes on the efficacy of fish oil and vitamin D, new treatments for heart failure patients, the cardiovascular effects of COVID-19 , and structural racism as a driver of health disparity were just a few of the major developments that emerged from the American Heart Association Scientific Sessions 2020, held virtually from Nov.

Research 52

Research Virus Therapies Trials 52

The Pharma Data

JUNE 26, 2021

JUNE 22 , 2021. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

FEBRUARY 22, 2021

If results are positive, Phase 3 study to start in Q2 2021, with vaccine expected to be available in Q4 2021. We look forward to further progressing this vaccine candidate to Phase 3 in Q2 2021, if this Phase 2 study is successful.”. If data from the new Phase 2 trial are positive, a global Phase 3 study is planned for Q2 2021.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

JANUARY 17, 2021

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. MUNICH, Germany, Jan.

Therapies 40

Therapies Research Virus Disease 40

The Pharma Data

MARCH 1, 2022

Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor under review for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.

FDA 52

FDA Treatment Science Therapies 52

The Pharma Data

MARCH 11, 2021

Expected to enroll 415 participants; interim results expected in Q3 2021. The Companies expect interim results from this trial in the third quarter of 2021. On February 22, 2021, GSK and Sanofi announced the beginning of a new Phase 2 study with an improved antigen formulation. About Translate Bio.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

DECEMBER 23, 2020

It’s almost 2021, and the whole world just wants to move on from COVID-19. While the overall understanding of the condition is as novel as the virus that causes it, a recent survey from the U.K.’s While the overall understanding of the condition is as novel as the virus that causes it, a recent survey from the U.K.’s

Clinical Trials 52

Clinical Trials FDA Small Molecule Trials 52

The Pharma Data

AUGUST 30, 2021

Pulmonary infection with the SARS-CoV2 virus can progress to acute respiratory distress syndrome (ARDS), in which inflammation and neutrophil hyperactivation play a central role. Given the central role played by neutrophils in ARDS, the team postulated that metoprolol might be an effective treatment for patients with severe COVID-19.

Clinical Trials 52

Clinical Trials Drugs Trials Hospitals 52

The Pharma Data

NOVEMBER 23, 2020

The Company is making rapid progress in manufacturing with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body. AstraZeneca.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

The Pharma Data

MARCH 18, 2021

Medicago’s plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK’s pandemic adjuvant. Food and Drug Administration (FDA) on 17 February 2021. Two doses of 3.75?g

Vaccine 52

Vaccine Trials Clinical Trials FDA 52

The Pharma Data

JANUARY 3, 2021

04, 2021 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that its subsidiary, InspirMed Inc., SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials Disease 52

The Pharma Data

MAY 4, 2021

Posted 04 May 2021 | By Michael Mezher . A Psychedelic Drug Passes a Big Test for PTSD Treatment ( NYTimes ) ( Endpoints ). WHO is closely monitoring 10 Covid variants as virus mutates around the world ( CNBC ) . Can a topical treatment beat blockbuster eye injectables? .

Vaccine 52

Vaccine FDA Approval FDA Licensing 52

The Pharma Data

DECEMBER 30, 2020

AstraZeneca is working with its global partners to continue building manufacturing capacity of up to three billion doses of the vaccine globally in 2021 on a rolling basis, pending regulatory approvals.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. Regeneron has partnered with Roche to increase the global supply of REGN-COV2 beginning in 2021.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

These follow-on data provided the first definitive prospective evidence demonstrating anti-viral activity for a treatment regimen now available for COVID-19, and also further documented the ability of this treatment to decrease the need for further medical attention,” said George D. Yancopoulos , M.D.,

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

APRIL 15, 2022

These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group. The neutralizing GMT against the wild-type virus was 2153 (after three doses), compared to 335 after two doses.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52